Key facts
- Manuals
- 1
- Languages
- EN
- Last added
- 2026-09-28
Featured GLAXOSMITHKLINE manuals

GlaxoSmithKline Pharmaceutical Products Third Amended Complaint
The document is a third amended complaint and jury demand filed in the United States District Court for the District of Massachusetts. It alleges that GlaxoSmithKline (formerly SmithKlineBeecham) submitted false claims for payment to the U.S. government and state Medicaid programs for defective or misidentified pharmaceutical products.
The complaint details numerous quality‑assurance failures at GSK's Cidra, Puerto Rico plant, including product mix‑ups, contamination, and inadequate process validation, and cites violations of the Federal False Claims Act and related state statutes.
Covers: Introduction · Jurisdiction and Venue · Parties · Overview of Factual Basis for False Claims · Summary of False Claims Act Liability · Damage to the Government
Latest GLAXOSMITHKLINE manuals
GlaxoSmithKline Pharmaceutical Products Third Amended Complaint
Other 140 pages · 373 KB · ENFederal complaint alleging false claims and quality‑assurance violations by GlaxoSmithKline's drug manufacturing operations.
Questions answered in GLAXOSMITHKLINE manuals
Which drugs are mentioned as being affected by the alleged violations?
The complaint lists drugs such as Paxil, Paxil CR, Avandia, Avandamet, Coreg, Bactroban, Abreva, Cimetidine, Compazine, Denavir, Dyazide, Thorazine, Stelazine, Ecotrin, Tagamet, Relafen, Kytril, Factive, Dyrenium and Albenza.
From: GlaxoSmithKline Pharmaceutical Products Third Amended Complaint
